 CAMBRIDGE, Mass. , Jan. 4, 2023 PRNewswire -- Nuvalent, Inc., Nasdaq: NUVL, a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D. 